Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

740 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Re: Toni K. Choueiri, Daniel Y.C. Heng, Jae Lyun Lee, et al. Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial. JAMA Oncol. In press. https://doi.org/10.1001/jamaoncol.2020.2218: SAVOIR: From Own Goal to Winning Goal?
Mollica V, Rizzo A, Massari F. Mollica V, et al. Among authors: massari f. Eur Urol Oncol. 2020 Aug;3(4):561-562. doi: 10.1016/j.euo.2020.06.008. Epub 2020 Jul 9. Eur Urol Oncol. 2020. PMID: 32653414 No abstract available.
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.
Santoni M, Conti A, Porta C, Procopio G, Sternberg CN, Basso U, De Giorgi U, Bracarda S, Rizzo M, Ortega C, Massari F, Iacovelli R, Derosa L, Masini C, Milella M, Di Lorenzo G, Atzori F, Pagano M, Buti S, De Vivo R, Mosca A, Rossi M, Paglino C, Verzoni E, Cerbone L, Muzzonigro G, Falconi M, Montironi R, Burattini L, Santini D, Cascinu S. Santoni M, et al. Among authors: massari f. J Urol. 2015 Jan;193(1):41-7. doi: 10.1016/j.juro.2014.07.011. Epub 2014 Jul 18. J Urol. 2015. PMID: 25046616
Cabozantinib in Advanced Renal Cell Carcinoma: Is it a METEOR?
Ciccarese C, Massari F, Tortora G. Ciccarese C, et al. Among authors: massari f. Eur Urol. 2016 May;69(5):969-70. doi: 10.1016/j.eururo.2015.12.030. Epub 2015 Dec 24. Eur Urol. 2016. PMID: 26724839 No abstract available.
Adjuvant therapy in renal cell carcinoma.
Massari F, Di Nunno V, Ciccarese C, Graham J, Porta C, Comito F, Cubelli M, Iacovelli R, Heng DYC. Massari F, et al. Cancer Treat Rev. 2017 Nov;60:152-157. doi: 10.1016/j.ctrv.2017.09.004. Epub 2017 Sep 23. Cancer Treat Rev. 2017. PMID: 28992528 Review.
Re: Michael B. Atkins, Elizabeth R. Plimack, Igor Puzanov, et al. Axitinib in Combination with Pembrolizumab in Patients with Advanced Renal Cell Cancer: A Non-randomised, Open-label, Dose-finding, and Dose-expansion Phase 1b Trial. Lancet Oncol 2018;19:405-15.
Di Nunno V, Santoni M, Massari F. Di Nunno V, et al. Among authors: massari f. Eur Urol. 2018 Aug;74(2):e50. doi: 10.1016/j.eururo.2018.04.015. Epub 2018 Apr 27. Eur Urol. 2018. PMID: 29709313 No abstract available.
Safety and Efficacy of Cabozantinib for Metastatic Nonclear Renal Cell Carcinoma: Real-world Data From an Italian Managed Access Program.
Prisciandaro M, Ratta R, Massari F, Fornarini G, Caponnetto S, Iacovelli R, De Giorgi U, Facchini G, Scagliarini S, Sabbatini R, Caserta C, Peverelli G, Mennitto A, Verzoni E, Procopio G. Prisciandaro M, et al. Among authors: massari f. Am J Clin Oncol. 2019 Jan;42(1):42-45. doi: 10.1097/COC.0000000000000478. Am J Clin Oncol. 2019. PMID: 30204614 Clinical Trial.
740 results